MedTrace Logo

Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

NCT00400114 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-05-08

No results posted yet for this study

Summary

The purpose of this study is to see whether or not the combination of cisplatin, irinotecan and radiation, followed by surgery, followed by oral Sutent, is effective and safe for patients with resectable esophageal cancer.

Conditions

  • Esophageal Cancer

Interventions

DRUG

Irinotecan

Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8

DRUG

Cisplatin

Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8

PROCEDURE

Radiation

Radiation 50 Gy (weeks 4-9)

PROCEDURE

Surgery

Esophagectomy

DRUG

sunitinib (Sutent)

sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Jennifer J Knox, MD M.Sc. FRCPC · University Health Network, Toronto

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-25
Primary Completion
2016-09-19
Completion
2016-09-19

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00400114 on ClinicalTrials.gov